Real‐World Treatment Patterns and Outcomes in Patients With Relapsed/Refractory Multiple Myeloma and 1–3 Prior Lines of Therapy: Optum Database
Cancer Medicine · 2025
DOI: 10.1002/cam4.71093 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2025. Verfasst von Binod Dhakal und 18 weiteren Autor:innen. Beteiligte Einrichtung: Medical College of Wisconsin, Milwaukee, Wisconsin, USA. Hauptthemen laut MEDLINE: Multiple Myeloma, Antineoplastic Combined Chemotherapy Protocols, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Legend Biotech, Johnson & Johnson, Johnson and Johnson.
Abstract (Originalsprache)
Background
Early (often continuous) treatment of multiple myeloma (MM) with lenalidomide has become common practice, leading to an increase in lenalidomide‐refractory disease.
Methods
We report real‐world treatment patterns, health care resource utilization (HCRU), and outcomes for patients with lenalidomide‐refractory MM using data from Optum US Claims and Optum electronic health record (EHR) databases with index date from January 2016 to March 2022 (Claims) or December 2021 (EHR). Eligible patients had received 1–3 prior lines of therapy (LOT), including a proteasome inhibitor.
Results
A total of 1383 and 1597 patients with lenalidomide‐refractory disease were included from the Claims and EHR databases, respectively, with median ages of 72 and 68 years and mean Charlson Comorbidity Index scores of 4.0 and 3.1. The most common treatment combinations were daratumumab–pomalidomide–dexamethasone, daratumumab–bortezomib–dexamethasone, and pomalidomide–dexamethasone (~5% each). From LOT 2 to LOT 6, treatment attrition (patients who died or received no further treatment) was 95.2% to 95.9%. Median time to next treatment was 5.4 (Claims) and 5.9 months (EHR). Median OS was 35.2 (Claims) and 41.2 months (EHR). HCRU was consistent across LOT.
Conclusions
Patients with lenalidomide‐refractory MM who received 1–3 prior LOT had poor outcomes and moved quickly through available therapies, demonstrating an unmet need to improve outcomes in this difficult‐to‐treat patient population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
- Universitätsklinikum Würzburg, Medizinische Klinik und Poliklinik II, Würzburg, Germany.
- Johnson & Johnson, Raritan, New Jersey, USA.
- Johnson & Johnson, Beerse, Belgium.
- Cilag GmbH International, Zug, Switzerland.
- Johnson & Johnson, Buenos Aires, Argentina.
ORCID-Profile: Binod Dhakal
Förderung
- Legend Biotech
- Johnson & Johnson
- Johnson and Johnson
Zitieren
APA
Dhakal, B., Einsele, H., Schecter, J. M., Deraedt, W., Lendvai, N., Slaughter, A., Lonardi, C., Nair, S., Varghese, N. E., He, J., Kharat, A., Lee, S., Cost, P., Potluri, R., Koneru, M., Patel, N., Florendo, E., Rodriguez-Otero, P., & Yong, K. (2025). Real‐World Treatment Patterns and Outcomes in Patients With Relapsed/Refractory Multiple Myeloma and 1–3 Prior Lines of Therapy: Optum Database. Cancer Medicine. https://doi.org/10.1002/cam4.71093
Vancouver
Dhakal B, Einsele H, Schecter JM, Deraedt W, Lendvai N, Slaughter A, et al. Real‐World Treatment Patterns and Outcomes in Patients With Relapsed/Refractory Multiple Myeloma and 1–3 Prior Lines of Therapy: Optum Database. Cancer Medicine. 2025. doi:10.1002/cam4.71093
BibTeX
@article{Dhakal2025,
author = {Dhakal, Binod and Einsele, Hermann and Schecter, Jordan M and Deraedt, William and Lendvai, Nikoletta and Slaughter, Ana and Lonardi, Carolina and Nair, Sandhya and Varghese, Nirosha Elsem and He, Jianming and Kharat, Akshay and Lee, Seina and Cost, Patricia and Potluri, Ravi and Koneru, Mythili and Patel, Nitin and Florendo, Erika and Rodriguez-Otero, Paula and Yong, Kwee},
title = {Real‐World Treatment Patterns and Outcomes in Patients With Relapsed/Refractory Multiple Myeloma and 1–3 Prior Lines of Therapy: Optum Database},
journal = {Cancer Medicine},
year = {2025},
doi = {10.1002/cam4.71093}
}
EUVIMED